Cardiff Oncology: Rises on starting mid-stage trial of pancreatic cancer treatment

Cardiff Oncology

08/06/2021 15:15

** Biotech co's shares  CRDF.O  rise 3.2% to $8.04
    ** Co says first patient dosed in its mid-stage trial of
onvansertib as a combination therapy for patients with
pancreatic cancer  urn:newsml:reuters.com:*:nPn32CT3Ra
    ** Says study designed to assess safety and preliminary
efficacy of its drug onvansertib in combination with
standard-of-care as a second-line treatment in patients with a
type of pancreatic cancer who have failed first-line therapy
    ** Trial expected to enroll about 40 patients across six
sites in the United States - co
    ** CRDF stock down about 55% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com;))